BTIG Research Has Lowered Expectations for Billiontoone (NASDAQ:BLLN) Stock Price

Billiontoone (NASDAQ:BLLN) had its target price dropped by BTIG Research from $160.00 to $140.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price objective suggests a potential upside of 73.20% from the company’s current price.

BLLN has been the subject of a number of other research reports. Wells Fargo & Company assumed coverage on Billiontoone in a research note on Monday, December 1st. They issued an “equal weight” rating and a $110.00 price target for the company. JPMorgan Chase & Co. cut their target price on Billiontoone from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Wednesday, December 10th. Guggenheim began coverage on Billiontoone in a report on Tuesday, January 6th. They issued a “buy” rating and a $120.00 price target on the stock. Stifel Nicolaus initiated coverage on Billiontoone in a research note on Monday, December 1st. They issued a “buy” rating and a $145.00 price target for the company. Finally, Jefferies Financial Group began coverage on shares of Billiontoone in a research report on Monday, December 1st. They set a “hold” rating and a $117.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $132.43.

Billiontoone Stock Down 2.8%

Billiontoone stock opened at $80.83 on Thursday. Billiontoone has a 12-month low of $66.00 and a 12-month high of $138.70. The stock has a market cap of $3.70 billion and a price-to-earnings ratio of 808.30. The business has a 50 day moving average price of $86.15.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.07. The firm had revenue of $96.05 million during the quarter, compared to the consensus estimate of $85.85 million. The company’s quarterly revenue was up 113.0% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Rossby Financial LCC bought a new stake in shares of Billiontoone in the 4th quarter valued at approximately $25,000. Wells Fargo & Company MN purchased a new stake in Billiontoone during the 4th quarter valued at $76,000. Smartleaf Asset Management LLC bought a new stake in Billiontoone in the fourth quarter worth $80,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Billiontoone during the fourth quarter worth $82,000. Finally, Renaissance Capital LLC bought a new position in Billiontoone during the fourth quarter valued at $201,000.

More Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: BLLN reported better-than-expected Q4 results: $0.11 EPS vs. $0.04 consensus and revenue up ~113% year-over-year — a clear beat that supports growth expectations. BillionToOne Q4 results and call
• Positive Sentiment: The company raised FY2026 revenue guidance to $430M–$445M versus a prior consensus near $356M — a material upward revision that implies meaningful topline acceleration and is a primary positive catalyst. GlobeNewswire press release
• Positive Sentiment: Management commentary and the earnings call highlighted record revenue growth and strategic initiatives to scale diagnostic adoption — supportive for medium-term execution. Earnings call highlights (Yahoo)
• Neutral Sentiment: Analysts (Zacks and others) are parsing key metrics versus estimates to assess sustainability of the growth beat; deeper metric analysis will inform revisions to models and investor expectations. Zacks earnings metrics analysis
• Neutral Sentiment: Company released the official press release and slide deck for the quarter — useful for investors building financial models but not a new catalyst by itself. Press release / slide deck
• Neutral Sentiment: Reported short-interest data in early March appears inconsistent (values show zero/NaN), so it’s not currently a reliable explanation for price moves; any future verified rise in short interest would be a potential headwind.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.